Merck's Q1 Earnings Beat Wall Street, Adjusts 2025 Profit Outlook As Tariffs May Result In Incremental Cost Of $200 Million
MRKMerck posted Q1 adjusted EPS of $2.22 and revenue of $15.53 billion, beating estimates while revising full-year guidance amid tariff-related cost pressure.
Merck & Co Lowers FY2025 Adj EPS Guidance from $8.88-$9.03 to $8.82-$8.97 vs $8.95 Est; Affirms FY2025 Sales Guidance of $64.10B-$65.60B vs $65.00B Est
MRKMerck & Co Q1 Adj. EPS $2.22 Beats $2.14 Estimate, Sales $15.53B Beat $15.31B Estimate
MRKWhy Is Summit Therapeutics Stock Soaring On Wednesday?
MRKSummit and Akeso report Phase 3 success as ivonescimab shows PFS gains in NSCLC trial, with new studies and collaborations underway.
Merck Stock Slumps Ahead Of Q1 Earnings: Can Bulls Find Relief In Buying Pressure?
MRKMerck & Co reports Q1 earnings on Thursday with EPS of $2.14 and revenue of $15.33B expected. Despite a 38.04% drop in stock over past year, analysts see ~30% upside potential.
Cantor Fitzgerald Initiates Coverage On Merck & Co with Neutral Rating, Announces Price Target of $85
MRKHealth Canada Has Approved Merck's Keytruda (Pembrolizumab) In Combination With Pemetrexed And Platinum Chemotherapy For The First-line Treatment Of Adult Patients With Unresectable Advanced Or Metastatic Malignant Pleural Mesothelioma.
MRKAssessing Merck & Co: Insights From 9 Financial Analysts
MRKGuggenheim Reiterates Buy on Merck & Co, Maintains $115 Price Target
MRKPrice Over Earnings Overview: Merck & Co
MRKMerck Signs Nearly $500 Million Licensing Deal With Austria-Based Cyprumed For Tablet-Based Peptide Delivery
MRKMerck signs deal with Austria's Cyprumed to develop oral peptide therapies, potentially paying up to $493 million for access to delivery technology.
'Merck Eyes Oral Peptide Delivery With Cyprumed Deal Worth Up To $493M' - BioSpace
MRKBeiGene Discontinues Lung Cancer Drug Study After Interim Data Showed Limited Survival Benefit
MRKBeiGene ends its Phase 3 lung cancer trial for ociperlimab after a futility analysis. No new safety concerns were found, and study results will be shared later.
How Do Investors Really Feel About Merck & Co?
MRKMerck Highlights Phase 3 ZENITH Trial Evaluating WINREVAIR; Says Trial Stopped Early Due To 'overwhelming efficacy demonstrated in the primary endpoint'
MRKMerck's Investigational Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Demonstrates Noninferior Pharmacokinetics Compared To Intravenous KEYTRUDA In Pivotal 3475A-D77 Trial; A Time And Motion Descriptive Analysis Shows Nearly 50% Reductions In Pat
MRKThe European Commission Has Approved Merck's Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) For Active Immunization For The Prevention Of Invasive Disease And Pneumonia Caused By Streptococcus Pneumoniae Serotypes In Individuals 18 Years Of Age And
MRKMerck Partners With Hengrui Pharma In $1.77 Billion Deal For Cardiovascular Treatment
MRKMerck secures global rights to HRS-5346, an investigational Lp(a) inhibitor, in a deal with Hengrui Pharma worth up to $1.97 billion.
Merck & Co Will Pay As Much As $2B For The Rights To Jiangsu Hengrui Pharmaceuticals Experimental Heart Drug
MRKMerck And Jiangsu Hengrui Pharmaceuticals Entered Into An Exclusive License Agreement For HRS-5346, An Investigational Oral Small Molecule Lipoprotein(a) Inhibitor Currently In A Phase 2 Trial In China, Hengrui Pharma Will Receive An Upfront Payment Of $2
MRKAnalyst Initiates Coverage On 'Undervalued' Summit Therapeutics
MRKSummit Therapeutics' ivonescimab shows strong efficacy in trials, with Cantor Fitzgerald predicting a 50% market share in the $100B VEGF x PD-(L)1 space.
Merck Announced That Health Canada Approved Keytruda (Pembrolizumab), Merck's Anti-PD-1 Therapy, In Combination With Carboplatin And Paclitaxel, Followed By Keytruda As A Single Agent, For The Treatment Of Adult Patients With Primary Advanced Or Recurrent
MRKMerck, Known As MSD Outside Of The United States And Canada, Announced That New Clinical And Outcomes Research Data Will Be Presented At The American College Of Cardiology's Annual Scientific Session And Expo In Chicago From March 29-31
MRKMerck & Co's Options: A Look at What the Big Money is Thinking
MRKPliant Therapeutics' Investigational Cancer Drug Shows Antitumor Activity Across Multiple Tumor Types
MRKPliant Therapeutics' PLN-101095 showed partial responses in ICI-refractory tumors, with a 50% ORR at the highest dose tested in its Phase 1 trial.
A Closer Look at Merck & Co's Options Market Dynamics
MRKHow Do Investors Really Feel About Merck & Co?
MRKMerck Plans Regulatory Submission For Two-Drug Regime For HIV Infection By Mid-2025
MRKMerck's DOR/ISL met primary efficacy and safety goals in two Phase 3 HIV trials. Marketing applications are planned for mid-2025.
Merck Announces Data From Phase 3 Trials That Show The Investigational, Once-Daily, Oral, Two-Drug Regimen Of Doravirine/Islatravir Maintained HIV-1 Viral Suppression At Week 48
MRKMerck announces Opening Of New $1B 225,000-Square-Foot Facility Dedicated To Vaccine Manufacturing At Its Durham, North Carolina Site
MRKMerck & Co Unusual Options Activity For March 10
MRKSpotlight on Merck & Co: Analyzing the Surge in Options Activity
MRKDecoding Merck & Co's Options Activity: What's the Big Picture?
MRKMerck's Keytruda Gains FDA Priority Review for Head and Neck Cancer Treatment
MRKLooking Into Merck & Co's Recent Short Interest
MRKEurope Approves Merck's Cancer Drug For Two Indications
MRKMerck's Welireg receives conditional EU approval for VHL disease-associated tumors and advanced RCC, expanding its global presence across 30+ countries.
Merck Vaccine Case With Ties to HHS Secretary Kennedy Delayed; Merck Agrees To Halt Ongoing Trial Over HPV Vaccine In Los Angeles Superior Court; Merck And Plaintiff Suing Over Alleged Gardasil Vaccine Injuries Agree To Delay Trial Until September 2025 Wi
MRKBeyond The Numbers: 13 Analysts Discuss Merck & Co Stock
MRKDeutsche Bank Downgrades Merck & Co to Hold, Lowers Price Target to $105
MRKEuropean Commission Conditionally Approves Merck's WELIREG As Monotherapy For Adults With von Hippel-Lindau And Advanced Clear Cell RCC
MRKDecoding Merck & Co's Options Activity: What's the Big Picture?
MRKGuggenheim Maintains Buy on Merck & Co, Lowers Price Target to $115
MRKNeuphoria Achieves $15M Milestone In Merck Partnership With Launch Of Phase 2 Clinical Trial
MRKPrice Over Earnings Overview: Merck & Co
MRKLeerink Partners Maintains Outperform on Merck & Co, Lowers Price Target to $119
MRKU.S. Fda Says Merck's Zinplava, Injection, 25 mg/1 ml To Be Discontinued On Jan 31, 2025
MRKMerck Disclosed Closing Of Exclusive Global License Agreement For LM-299, A Novel Investigational PD-1/VEGF Bispecific Antibody From LaNova Medicine; Company To Record Pre-tax Charge Relating To Upfront Payment Of $588M, Or $0.18 Per Share, In Q4 2024 GAA
MRKBMO Capital Downgrades Merck & Co to Market Perform, Lowers Price Target to $105
MRKMerck's Investigational Two-Drug Regime For HIV Meets Primary Goal In Two Late-Stage Trials
MRKMerck shares Phase 3 trial results for its HIV-1 regimen, doravirine/islatravir, showing safety and comparable efficacy to existing therapies.
Merck Agrees To Purchase $50M Of Personalis Common Stock In A Private Placement At A Price Of $3.56 Per Share
MRK